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Abstract
© 2015 Park-media,  Ltd.  Organophosphate  toxins  (OPs)  are  the  most  toxic  low-molecular
compounds. The extremely potent toxicity of OPs is determined by their specificity toward the
nerve system. Human butyrylcholinesterase (hBChE) is a natural bioscavenger against a broad
spectrum of OPs, which makes it a promising candidate for the development of DNA-encoded
bioscavengers.  The  high  values  of  the  protective  index  observed  for  recombinant  hBChE
(rhBChE) make it appropriate for therapy against OP poisoning, especially in the case of highly
toxic warfare nerve agents. Nevertheless, large-scale application of biopharmaceuticals based
on  hBChE  is  restricted  due  to  its  high  cost  and  extremely  rapid  elimination  from  the
bloodstream.  In  the  present  study,  we  examine  two  approaches  for  long-acting  rhBChE
production: I) chemical polysialylation and II) in-vivo tetramerization. We demonstrate that both
approaches significantly improve the pharmacokinetic characteristics of rhBChE (more than 5
and 10 times, respectively), which makes it possible to use rhBChE conjugated with polysialic
acids (rhBChE-CAO) and tetrameric rhBChE (4rhBChE) in the treatment of OP poisonings.
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